The publication of this content was funded by Accord Healthcare. The views and opinions expressed are exclusively those of the speakers.
The opinions expressed in this content belong solely to the named speakers. ORGOVYX▼ (relugolix) is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. If you are a HCP in the EU, prescribing information can be found here. If you are a GB HCP, prescribing information can be found here.
| Adverse events should be reported. For UK healthcare professionals, reporting forms, and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Accord-UK LTD on 01271 385257 or email [email protected]. For non-UK/EU healthcare professionals, you can report side effects directly via the national reporting system listed in Appendix V of the EU SmPC. |
This industry symposium took place on 5th April 2024 during the 39th Annual European Association of Urology (EAU) Congress in Paris, France.
Timestamps:
00:00–03:40: Welcome, Introductions, and Objectives (Eva Hellmis and Amit Bahl)
03:41–18:29: ADT in 2024 – What Do Our Patients Expect? (Andrew Gabriel)
18:30–27:20: ADT in 2024 – What Do We Offer Our Patients? (Romain Mathieu)
27:21–41:30: ADT in 2024 – What Do We Say to Our Patients? (Amit Bahl)
41:31–47:14: Panel Discussion (Moderated by Eva Hellmis)
Speakers:
Eva Hellmis, Urologicum Duisburg, Germany
Amit Bahl, Bristol Cancer Institute, University Hospitals Bristol, UK
Andrew Gabriel, Hampshire, UKRomain Mathieu, Centre Hospitalier Universitaire (CHU) Pontchaillou, Rennes, France
Job code: EUR-Onc-Org-01476
Date of prep: October 2024
